Healthcare providers often recommend Eligard® (leuprolide acetate) to treat advanced prostate cancer. This medication comes in injectable form and is administered via subcutaneous injection every one, three, four, or six months, depending on various factors.
Eligard may decrease bone density, which could lead to bone loss and increase your risk for osteoporosis and fractures. People who already have osteoporosis, or who have risk factors for this condition, such as people who regularly use alcohol or tobacco or who have a family history of osteoporosis, may be at greater risk.
(To learn more about the risk of bone loss with this medication, click Eligard Warnings and Precautions. This article also provides other important safety considerations to keep in mind during treatment.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Eligard [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC;2011 March.
Eligard Web site. Available at: http://www.eligard.com. Accessed June 14, 2011.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click